Skip to main content
×
Home
    • Aa
    • Aa

Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial

  • C. R. Hjorthøj (a1), A. Fohlmann (a1), A.-M. Larsen (a1), C. Gluud (a2), M. Arendt (a3) and M. Nordentoft (a1)...
Abstract
Background

Cannabis abuse in psychotic patients is associated with rehospitalizations, reduced adherence and increased symptom severity. Previous psychosocial interventions have been ineffective in cannabis use, possibly because of low sample sizes and short interventions. We investigated whether adding CapOpus to treatment as usual (TAU) reduces cannabis use in patients with cannabis use disorder and psychosis.

Method

A total of 103 patients with psychosis and cannabis use disorder were centrally randomized to 6 months of CapOpus plus TAU (n = 52) or TAU (n = 51). CapOpus consisted mainly of motivational interviewing and cognitive behaviour therapy (CBT). TAU was targeted primarily at the psychotic disorder. The primary outcome was self-reported days with cannabis use in the preceding month.

Results

Pre-randomization cannabis use frequency was 14.9 [95% confidence interval (CI) 12.7–17.1] days/month. Post-treatment, the ratio of days/month with cannabis use in CapOpus versus TAU was 0.76 (95% CI 0.38–1.50) (p = 0.42), and 0.80 (95% CI 0.21–3.10) (p = 0.75) at the 4-month follow-up. From 46.4 (95% CI 36.4–56.3) monthly joints pre-randomization, consumption fell to 27.3 (95% CI 12.6–41.9) joints in CapOpus and 48.2 (95% CI 31.8–64.6) in TAU (p = 0.06). Follow-up amounts were 28.4 (95% CI 13.5–43.2) and 41.6 (95% CI 25.2–58.0) joints (p = 0.23). Several subgroup analyses suggested benefits of CapOpus.

Conclusions

CapOpus did not reduce the frequency, but possibly the amount, of cannabis use. This is similar to the findings of previous trials in this population. Implementation of CapOpus-type interventions is thus not warranted at present but subgroup analyses call for further trials.

Copyright
Corresponding author
*Address for correspondence: C. R. Hjorthøj, Ph.D., M.Sc., Copenhagen University Hospital, Mental Health Centre Copenhagen, Research Unit, Bispebjerg Bakke 23, Building 13A, DK-2400 Copenhagen NV, Denmark. (Email: Carsten.Rygaard.Hjorthoej@regionh.dk)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

A Baker , S Bucci , TJ Lewin , F Kay-Lambkin , PM Constable , VJ Carr (2006). Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. British Journal of Psychiatry 188, 439448.

CBarrowclough , GHaddock , NTarrier , SWLewis , JMoring , RO'Brien , NSchofield , JMcGovern (2001). Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry 158, 17061713.

C Barrowclough , G Haddock , T Wykes , R Beardmore , P Conrod , T Craig , L Davies , G Dunn , E Eisner , S Lewis , J Moring , C Steel , N Tarrier (2010). Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. British Medical Journal 341, c6325.

ASBellack , MEBennett , JSGearon , CHBrown , YYang (2006). A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry 63, 426432.

GBersani , VOrlandi , SGherardelli , PPancheri (2002). Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology 35, 289295.

C Bonsack , MS Gibellini , J Favrod , Y Montagrin , J Besson , P Bovet , P Conus (2011). Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. Psychotherapy and Psychosomatics 80, 287297.

CRBowie , PDHarvey (2006). Administration and interpretation of the Trail Making Test. Nature Protocols 1, 22772281.

J Brandt (1991). The Hopkins verbal learning test: development of a new memory test with six equivalent forms. Clinical Neuropsychologist 5, 125142.

RBrooks (1996). EuroQol: the current state of play. Health Policy 37, 5372.

D Caspari (1999). Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience 249, 4549.

MCleary , GHunt , SMatheson , NSiegfried , GWalter (2008). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews. Issue 1, Art. No. CD001088.

WM Compton , BF Grant , JD Colliver , MD Glantz , FS Stinson (2004). Prevalence of marijuana use disorders in the United States. Journal of the American Medical Association 291, 21142121.

BA Cornblatt , MF Lenzenweger , L Erlenmeyer-Kimling (1989). The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Research 29, 6585.

DC D'Souza , WM Abi-Saab , S Madonick , K Forselius-Bielen , A Doersch , G Braley , R Gueorguieva , TB Cooper , JH Krystal (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594608.

JEdwards , KElkins , MHinton , SMHarrigan , KDonovan , OAthanasopoulos , PDMcGorry (2006). Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica 114, 109117.

J Endicott , RL Spitzer , JL Fleiss , J Cohen (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766771.

AGrech , Jvan Os , PBJones , SWLewis , RMMurray (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry 20, 349353.

BGreen , RYoung , DKavanagh (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 187, 306313.

RW Heinrichs , KK Zakzanis (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426445.

L Hides , S Dawe , DJ Kavanagh , RM Young (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry 189, 137143.

CHjorthøj , AFohlmann , A-MLarsen , MTMadsen , LVesterager , CGluud , MCArendt , MNordentoft (2008). Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Trials 9, 42.

C Hjorthøj , A Fohlmann , M Nordentoft (2009). Treatment of cannabis use disorders in people with schizophrenia spectrum disorders – a systematic review. Addictive Behaviors 34, 520525.

CR Hjorthøj , A Fohlmann , AM Larsen , M Arendt , M Nordentoft (2012 a). Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 107, 11231131.

CR Hjorthøj , AR Hjorthøj , M Nordentoft (2012 b). Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances – systematic review and meta-analysis. Addictive Behaviors 37, 225233.

JMJerrell , MSRidgely (1995). Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. Journal of Nervous and Mental Disease 183, 566576.

MKamali , BDKelly , MClarke , SBrowne , MGervin , AKinsella , ALane , CLarkin , EO'Callaghan (2006). A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry 21, 2933.

DJKavanagh , RYoung , AWhite , JBSaunders , JWallis , NShockley , LJenner , AClair (2004). A brief motivational intervention for substance misuse in recent-onset psychosis. Drug and Alcohol Review 23, 151155.

SRKay , AFiszbein , LAOpler (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.

RSEKeefe , TEGoldberg , PDHarvey , JMGold , MPPoe , LCoughenour (2004). The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 68, 283297.

RKemp , AHarris , EVurel , TSitharthan (2007). Stop Using Stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australasian Psychiatry 15, 490493.

DL Larsen , CC Attkisson , WA Hargreaves , TD Nguyen (1979). Assessment of client/patient satisfaction: development of a general scale. Evaluation and Program Planning 2, 197207.

VC Leeson , I Harrison , MA Ron , TRE Barnes , EM Joyce (2012). The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophrenia Bulletin 38, 873880.

SMartino , KMCarroll , CNich , BJRounsaville (2006). A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 101, 14791492.

HE Nelson , A O'Connell (1978). Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 14, 234244.

MNordentoft , HCKnudsen , BJessen-Petersen , AKrasnik , HSælan , PTreufeldt , BWetcher (1996). CCPP – Copenhagen Community Psychiatric Project. Implementation of community mental health centres in Copenhagen: effects of service utilization, social integration, quality of life and positive and negative symptoms. Social Psychiatry and Psychiatric Epidemiology 31, 336344.

M Olfson , D Mechanic , S Hansell , CA Boyer , J Walkup , PJ Weiden (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 51, 216222.

LPetersen , PJeppesen , AThorup , MBAbel , JOhlenschlaeger , TOChristensen , GKrarup , PJorgensen , MNordentoft (2005). A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal 331, 602.

SPriebe , PHuxley , SKnight , SEvans (1999). Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry 45, 712.

D Schofield , C Tennant , L Nash , L Degenhardt , A Cornish , C Hobbs , G Brennan (2006). Reasons for cannabis use in psychosis. Australian and New Zealand Journal of Psychiatry 40, 570574.

KFSchulz , DGAltman , DMoher (2010 a). CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. British Medical Journal 340, c332.

KFSchulz , DGAltman , DMoher , DFergusson (2010 b). CONSORT 2010 changes and testing blindness in RCTs. Lancet 375, 11441146.

LC Sobell , MB Sobell (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In Measuring Alcohol Consumption: Psychosocial and Biological Methods (ed. R. Z. Litten and J. Allen), pp. 4172. Humana Press: New Jersey.

J van Os , M Bak , M Hanssen , RV Bijl , R de Graaf , H Verdoux (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 156, 319327.

AM Weinstein , DA Gorelick (2011). Pharmacological treatment of cannabis dependence. Current Pharmaceutical Design 17, 13511358.

JK Wing , T Babor , T Brugha , J Burke , JE Cooper , R Giel , A Jablenski , D Regier , N Sartorius (1990). SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 589593.

MYücel , EBora , DILubman , NSolowij , WJBrewer , SMCotton , PConus , MJTakagi , AFornito , SJWood , PDMcGorry , CPantelis (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38, 316330.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: